Bivision Pharmaceuticals

Bivision Pharmaceuticals (晶核生物, also known as CoreVision Biopharma) is a China-based biotech company founded in 2021 that develops targeted radiopharmaceutical therapies (TRT) combining visualization and treatment, an approach described as "theranostic" . The company has built a proprietary technology platform for targeted nuclear drug development and established what it calls a first-mover advantage in China's targeted radiopharmaceutical sector . Its funding history shows Gaorong Ventures led its nearly RMB 100 million angel round in 2022 , followed by a Series A in mid-2024 co-led by Huajin Capital and Huajin Avenue with Gaorong reinvesting as an existing shareholder , and most recently a nearly RMB 400 million Series B in May 2026 co-led by Pudong Venture Capital, Zhangjiang Sci-Tech Investment and IDG Capital, again with Gaorong adding to its position . The company signed a clinical priority supply agreement for Lu-177 isotope in 2023 and had its first candidate drug enter clinical development that year .